Vaxzevria COVID-19 aşısı sonrasında gelişen şiddetli büllöz pemfigoid

Pfizer ve Moderna COVID-19 aşılarına sekonder büllöz pemfigoid az sayıda olguda tanımlanmıştır. Bu, Oxford-AstraZeneca Vaxzevria COVID-19 aşısı tarafından tetiklenen bildirilmiş ilk büllöz pemfigoid vakasıdır. Olgunun ilk semptomları, aşının ilk dozundan dört hafta sonra ortaya çıkmış ve büllöz pemfigoid tanısı direkt immünofloresan test ve BP180 antikor pozitifliği ile doğrulanmıştır.

Severe bullous pemphigoid after Vaxzevria COVID-19 vaccination

Bullous pemphigoid has been described in a small number of cases secondary to the Pfizer and Moderna COVID-19 vaccinations. This is the first reported case of bullous pemphigoid triggered by the Oxford-AstraZeneca Vaxzevria COVID-19 vaccination. His first symptoms occurred four weeks after his first dose, and were confirmed on direct immunofluorescence and with positive BP180 antibodies.

___

  • Wijayanti A, Zhao CY, Boettiger D, et al. The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for Bullous Pemphigoid: which one to use? Acta Derm Venereol 2017;97:24-31.
  • Tomayko MM, Damsky W, Fathy R, et al. Subepidermal blistering eruptions, including bullous pemphigoid, following Covid-19 vaccination. J Allergy Clin Immunol 2021;148:750-1.
  • Larson V, Seidenberg R, Caplan A, Brinster NK, Meehan SA, Kim RH. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol 2022;49:34-41.
  • Perez-Lopez I, Moyano-Bueno D, Ruis-Villaverde R. [Bullous pemphigoid and Covid-19 vaccine]. Med Clin (Barc) 2021;157:e333-e334.